Method and devices for rapid diagnosis of foot-and-mouth disease

ABSTRACT

A rapid immunoassay method and apparatus for detecting foot and mouth disease virus are disclosed. The method and test device permit pen-side testing of animals and provide test results within a relatively short time period. In a preferred embodiment, the method and apparatus provide a means for differentiating between FMDV-infected and FMDV-vaccinated animals.

CROSS REFERENCE TO RELATED APPLICATION

This application is a Divisional of U.S. patent application Ser. No.10/833,933 filed on Apr. 28, 2004, which in turns claims priority toKorean Application No. 10-2003-0026809 filed Apr. 28, 2003.

FIELD OF THE INVENTION

The present invention relates to the field of immunology, and to amethod of detecting antibodies to structural and/or non-structuralproteins of animal foot-and-mouth disease virus and, more particularly,to provide a rapid, one step qualitative, sensitive, and specificimmunochromatographic assay.

BACKGROUND OF THE INVENTION

Foot and mouth disease (FMD) is a devastating and extremely contagiousdisease of livestock. Its severity is such that the Office Internationaldes Epizooties has listed it as an A disease. All species of the orderof Artiodactyla, such as, but not limited to, pig, hog, javelina,hippopotamus, camel, llama, mouse deer, giraffe, okapi, deer, pronghorn,antelope, cattle, goat, and sheep, are susceptible to infection withFMD. The financial losses due to infection from the FMD Virus (FMDV) aresignificant. For example, there are direct losses due to deaths in younganimals, loss of milk and loss of meat, as well as decreases inproduct(s) yield. The costs associated with eradication of infectedanimals, as well as the costs required to limit the spread of FMDV tonon-infected animals, are high. Additionally, there are indirect lossesdue to the imposition of trade restrictions.

The causative agent of FMD is foot-and-mouth disease virus (FMDV), anaphthovirus of the Picornaviridae family (Bittle et al., 1982 and Frosset al., 1984). The FMDV genome consists of a single RNA positive strandof approximately 8,000 nucleotide bases. The viral RNA is initiallytranslated as a single polypeptide that is subsequently cleaved byviral-encoded proteases to produce four structural capsid proteins(VP1-VP4) and four non-structural proteins (2C, 3A, 3ABC and 3D). Thecoding region for structural and nonstructural proteins is shownschematically in FIG. 1.

FMDV is antigenically heterogeneous. Seven distinct serotypes have beenrecognized: O, A, C, ASIA1, SAT1, SAT2 and SAT3 (SAT=Southern AfricanTerritories). Each serotype of FMDV is antigenically distinct from theother six serotypes. Serotype A viruses are the most variable, havingmore than 30 subtypes. Furthermore, each serotype can be subdivided intoantigenically distinct multiple subtypes. The serotypes of FMDV wereoriginally identified by cross-immunity experiments in animals. Althoughan animal that has recovered from infection with one serotype isresistant to challenge by that same serotype, it still remainssusceptible to infection by any of the other serotypes.

The different serotypes of FMDV are most prevalent in certain geologicalareas. For instance, in Asia serotypes A, O, and ASIA1 are most common;in Europe and South America, serotypes A, O, and C are found; and inAfrica, serotypes A, O, and SAT are prevalent.

Following infection with FMDV, specific antibodies (IgG and/or IgM, IgA)against the structural proteins (SPs) and non-structural proteins (NSPs)appear. The antibody titers rapidly increase over time and remain high.Thus, the presence of specific FMDV antibody in a sample indicates thatthe animal from which the sample was collected has had contact with FMDVor an antigen derived from FMDV (such as, but not limited to, animalsthat have been vaccinated).

Diagnosis of FMD

Primary diagnosis of FMDV commonly involves recognition of typicalclinical signs in affected animals. Clinical signs of FMD areessentially similar in all species although the severity may varyconsiderably. The principal signs are pyrexia, followed by vesicleformation in the mouth and on the feet. Vesicle formation in the mouthcauses the animals to salivate. The vesicle formation on the feet causeslameness.

Serological diagnosis of FMD is determined by the presence ofFMDV-specific antigens or antibodies in animals suspected of having beeninfected. The current method of detection is by an enzyme-linkedimmunosorbent assay (ELISA) or by a virus neutralization test. Thesemethods require multiple steps, are time consuming, and are tedious toperform. Additionally, these assays require long incubation times,resulting in a significant delay in the diagnosis. Time is critical, asFMD is highly contagious. Thus any delay in diagnosis will result in therapid spread of the disease to uninfected animals, causing a greaterloss in product, and subsequently a greater financial loss.

The invention presented herein overcomes these insufficiencies byproviding a rapid, one-step method of detecting antibodies and/orantigens in a fluid sample from an animal suspected of having beeninfected. Additionally, the method presented herein allows for the rapiddetermination of protection from infection in those animals that havebeen vaccinated. Furthermore, the disclosed invention is able todetermine if an animal has been exposed to FMDV, either by infection orby vaccination, within 30 minutes.

Clinical Symptoms of FMD are not a Reliable Indicator of FMDV Infection

The invention provided herein allows for the rapid detection of antibodyto FMDV. Vesicular material is not always available from animals thathave been infected with FMDV, thus an additional advantage provided bythe present invention is that a liquid sample from animals suspected ofhaving been exposed to FMDV are diagnosed within 30 minutes. Currentmethodology requires multiple steps (each of which is a potential sourceof error) and days of incubation(s) prior to obtaining a result.Additionally, diagnosis of FMD by clinical signs alone is difficult,especially for sheep and goats, in which clinical signs are often mild(Barnett, P. V et al., 1999 and Callens, M., K. et al., 1998).Furthermore, several other vesicular virus infections, including, butnot limited to, those caused by swine vesicular disease (SVD) virus andvesicular stomatitis virus (VSV), cannot be distinguished from FMDVinfection by the clinical findings. Thus, a rapid diagnosis of theinfectious agent is critical.

Moreover, FMDV can establish a persistent or carrier stage in ruminantsin the absence of any clinical manifestation of the disease. Suchcarrier animals are a source of new outbreaks of the disease. Therefore,there is a long sought, yet unfulfilled, need for a rapid serologicalmethod in which infected and/or asymptomatic carrier animals areidentified. Additionally, there is a long sought, yet unfulfilled, needfor an assay system that will distinguish between animals that areprotected from FMDV infection, i.e., those that have been vaccinated,from animals that have been infected with FMDV. Since both vaccinationagainst FMDV and FMDV infection induced antibodies to the structuralcapsid proteins, assays that detect the structural capsid protein aloneare insufficient to differentiate vaccinated animals from those thathave been infected. Thus, antibodies against structural proteins canonly be used in vaccine-free regions, such as, but not limited to, theUSA or the UK. Assay systems that can only detect these anti-structuralprotein antibodies are therefore not useful in regions where animals arevaccinated. Since unvaccinated animals present in the geographic regionswhere vaccinations are given remain susceptible to infection with FMDV,there is a long sought, yet unfulfilled, need for a diagnostic test thatwill differentiate an infected animal from one that has been vaccinated(and thus protected from infection). The invention disclosed hereinprovides such an assay system.

The present invention further provides an assay system that will measurethe efficacy of vaccinations. The present invention disclosed hereinprovides for the current deficiencies in the art by providing an assaysystem that allows for the rapid detection of antibodies to both SPs andNSPs, thereby allowing for vaccinated animals to be differentiated fromthose that are infectious. Finally, the present invention provides adetection method that allows for rapid analysis of the geographicdistribution of specific FMDV serotypes and/or serotype subtypes forepidemiological studies.

Thus the present invention provides a rapid immunochromatographic assaywherein E. coli-expressed recombinant FMDV structural and non-structuralproteins are incorporated into a solid support for the capture ofantibodies to FMDV in animal body fluids. The immunochromatographicassay disclosed herein allows for the diagnosis of FMDV infection, forthe identification of FMDV carriers, as well as for the ability todifferentiate between an infected animal and an animal that has beenvaccinated (and thus protected from FMDV).

Abbreviations

“SP” means “structural protein or structural capsid protein

“NSP” means “non-structural protein”

“FMD” means “foot-and-mouth disease”

“FMDV” means “foot-and-mouth disease virus”

“ELISA” means “enzyme linked immunosorbent assay”

“PBS” means “phosphate buffered saline”

“PCR” means “polymerase chain reaction”

“PMSF” means “phenyl methyl sulfonyl fluoride”

“BSA” means “bovine serum albumin”

“Tris-HCl ” means “tris(hydroxymethyl)aminomethane-hydrochloride”\

“EDTA” means “ethylenediaminetetraacetic acid”

“IPTG” means “isopropylthiogalactoside”

“SDS-PAGE” means “sodium dodecyl sulfate-polyacrylamide gelelectrophoresis”\

“RT-PCR” means “reverse transcription-polymerase chain reaction”

“IgG” means “Immunoglobulin G”

“IgM” means “Immunoglobulin M”

“LB” means “Luria-Bertani ”

“DTT” means “dithiothreitol

Definitions

“TE” is 10 mM Tris-HCl, pH 8.0 (Sigma-Aldrich) and 1 mM EDTA, pH 8.0(Sigma-Aldrich)”

“Body fluid” is any substance that emanates or derives from the body,including but not limited, to blood, urine, tears, saliva, and breastmilk.

“Analyte” is the substance to be detected which may be present in thetest sample. The analyte can be any substance for which there exists anaturally occurring specific binding member (such as, but not limitedto, an antibody), or for which a specific binding member can beprepared. Thus, an analyte is a substance that can bind to one or morespecific binding members. Analytes include, but are not limited, toantigenic substances, haptens, antibodies, and combinations thereof.

“Labels” for use in the present invention can include, but are notlimited to, chromogens; catalysts; fluorescent compounds;chemiluminescent compounds; radioactive elements; colloidal metallic(such as gold), non-metallic (such as selenium) and dye particles;enzymes; enzyme substrates; organic polymer latex particles, liposomesor other vesicles containing such signal producing substances; etc. Alarge number of enzymes suitable for use as labels include, but are notlimited to, phosphatases and peroxidases, such as alkaline phosphataseand horseradish peroxidase which are used in conjunction with enzymesubstrates, such as nitro blue tetrazolium,3,5′,5,5′-tetranitrobenzidine, 4-methoxy-1-naphthol,4-chloro-1-naphthol, 5-bromo-4-chloro-3-indolyl phosphate,chemiluminescent enzyme substrates such as the dioxetanes, andderivatives and analogs thereof. Fluorescent compounds such asfluorescein, phycobiliprotein, rhodamine and the like, including theirderivatives and analogs are suitable for use as labels.

“Capture reagent” refers to an unlabeled specific binding member whichis specific either for the analyte, for the indicator reagent, or for anancillary specific binding member. The capture reagent can be directlyor indirectly bound to a solid phase material before the performance ofthe assay or during the performance of the assay, thereby enabling theseparation of immobilized complexes from the test sample.

“Specific binding member” or “specific binding agent” or “labeledbinding partner” refers to one member or partner of a specific bindingpair. A “specific binding pair” or “specific binding complex” refers totwo different molecules wherein one of the molecules, through chemicalor physical means, specifically binds to the second molecule. A typicalexample of specific binding members or agents which constitute aspecific binding pair are an antigen and an antibody. Other specificbinding pairs include, but are not limited to, biotin and avidin,protein G and/or A and immunoglobulin, carbohydrates and lectins,cofactors and enzymes, enzyme inhibitors and enzymes, effector andreceptor molecules, and the like. Furthermore, specific binding pairscan include members that are analogs of the original specific bindingmembers, for example, an analyte-analog. Immunoreactive specific bindingmembers include antigens, antigen fragments, antibodies, antibodyfragments, both monoclonal and polyclonal, and complexes thereof.

“Signal producing system” refers to a system that has at least twomembers: a catalytic member and a solute, which undergoes a reactioncatalyzed by the catalytic member, which leads directly or indirectly toa product on or in the surface which provides a detectible signal. Thecatalytic member may be enzymatic or non-enzymatic. The solute is anycompound which is capable of undergoing a reaction catalyzed by acatalytic member of the signal producing system, which reaction resultseither directly or indirectly in a detectible signal generatingcompound. The signal-generating compound will provide aspectrophotometric or visible signal, an electrochemical signal or anelectronically detectible signal. The observed detectible signal isrelated to the amount of catalyst bound through the binding of thecatalyst-bound-analyte, which in turn is related to the amount ofanalyte in the test sample.

“Ancillary reagent” refers to an additional reagent(s) included in theassay. Ancillary reagents include, but are not limited to, enzymesubstrates, cofactors, activators, scavengers, inhibitors or the like.In addition, buffers will normally be present, as well as stabilizers.Frequently in addition to these additives, additional proteins may beincluded, such as albumins; or surfactants, particularly non-ionicsurfactants, e.g. polyalkylene glycols, or the like.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram of the genetic map of FMDV RNA andproteins.

FIG. 2 is an elevation view of the strip configuration of the assaydevice.

FIG. 3 is a schematic diagram of an assay for the detection of antibodyin the sample.

FIG. 4 is the nucleotide and amino acid sequence of the VP-1 protein.

FIG. 5 is the plasmid map of pBM -VP1Tw97F.

FIG. 6 is the nucleotide and amino acid sequence of the 2C protein

FIG. 7 is the plasmid map of pBM-2CTw97F

FIG. 8 is the nucleotide and amino acid sequence of the 3ABC protein

FIG. 9 is the plasmid map of pBM-3ABCTw97F

FIG. 10 is the nucleotide and amino acid sequence of the 3D protein

FIG. 11 is the plasmid map of pBM-3DTw97F

FIG. 12 is a schematic diagram of the test kit formulation.

FIG. 13 is a schematic diagram of the two-line test kit configuration.

FIG. 14 is a chart comparing test results over time of a 3ABC ELISA andthe test of the presenting invention for an FMDV-infected cow.

FIG. 15 is a chart comparing test results over time of a 3ABC ELISA andthe test of the presenting invention for a second FMDV-infected cow.

FIG. 16 is a chart comparing test results over time of a 3ABC ELISA andthe test of the presenting invention for an FMDV-infected pig.

FIG. 17 is a chart comparing test results over time of a 3ABC ELISA andthe test of the presenting invention for a second FMDV-infected pig.

DETAILED DESCRIPTION OF THE INVENTION

The Test Device

The present invention relates to a device for the detection of ananalyte in a sample of biological fluid through the use ofimmunochemical ligand-receptor reactions and specially selected,treated, and arranged filter materials (FIG. 2; see also U.S. Pat. No.5,559,041 which is hereby incorporated by reference). The presentinvention includes a non-reactive cover (also referred to as anenclosure or casing) around the device. The cover encloses at least thestrip to avoid contact with, and contamination of, the capture sites. Inone embodiment, the cover also includes a raised area adjacent to theapplication pad to facilitate receiving and/or containing a certainvolume of the test sample and/or wicking solution. In a furtherembodiment of the invention, the cover includes a cut out area or areasin the form of a letter, number, icon, or symbol or any combinationthereof. In this embodiment, the cut out area or areas form the designfor a particular capture site(s) once the strip is completely enclosed.In another embodiment of the invention, a sufficient portion of thestrip is encased to prevent the applied test sample from contacting thecapture sites without first passing through a portion of the strip.

The Application Pad

It is contemplated and within the scope of the present invention thatthe solid phase can be any suitable porous material with sufficientporosity to allow access by detection antibodies and/or antigens and asuitable surface affinity to bind antigens and/or antibodies.Microporous structures, in general, are preferred, but materials withgel structure in the hydrated state may be used as well. Such usefulsolid supports include, but are not limited to, nitrocellulose,cellulose acetate, poly (vinyl chloride), polyacrylamide, polyacrylate,polyethylene, polypropylene, poly(4-methylbutene), polystyrene,polymethacrylate, poly(ethylene terephthalate), nylon, poly(vinylbutyrate), porous polyethylene frit or pads, and glass fiber filterpaper; either used by themselves or in conjunction with other materials.

The surface of such supports may be activated by chemical processes thatcause covalent linkage of the antigen and/or antibody to the support.Alternatively, the irreversible binding of the antigen and/or antibodyis obtained by adsorption on the porous material by poorly understoodhydrophobic forces. Other suitable solid supports are well known tothose of skill in the art. It is also well known in the art that thematerial chosen for the solid support(s) is one that is compatible withthe analyte and assay reagents used.

2 Pad System/3 Pad System

The filter pad 11 is separate and distinct from said reservoir pad 10,and wicking membrane 15, and interposed between and contiguous with thewicking membrane 15, and the reservoir pad 10′ (3 Pad system). Or onefilter pad 11′ functions as both reservoir 10′ and filter zone (2 Padsystem). The filter zone has impregnated therein a labelledimmunochemical component capable of binding to an analyte of interest insample to form an immuno-complex. The filter zone is operable to permitpassage of any specific immuno-complex to the wicking membrane 15, whileimpeding passage of larger components then contained in the sample; andat least one immobilized substance disposed in at least one assayindicia zone 4 of the wicking membrane 15 downstream of the filter zoneand defining assay indicia 13, the immobilized substance being operableto bind a specific immuno-complex contained in the sample to form theassay indicia 13.

Reagents Are Incorporated Within The Test Device

In addition, the application pad typically contains one or more assayreagents either diffusively or non-diffusively attached thereto.Reagents that are contained in the application pad include, but are notlimited to, labeled reagents, ancillary specific binding members, and/orsignal producing system components needed to produce a detectablesignal. The isolation of assay reagents in the application pad alsoseparates the interactive reagents, thereby facilitating themanufacturing process.

In an embodiment of the present invention, predetermined amounts ofsignal producing components and ancillary reagents are incorporatedwithin the device, thereby avoiding the need for additional protocolsteps or reagent additions. Thus, it also is within the scope of thisinvention to provide more than one reagent to be immobilized within theapplication pad and/or the strip material.

This invention covers detection method for FMDV antibody, PRRSV(PorcineRespiratory and Reproductive Symptom Virus) antibody and antigen,FeLV(Feline Leukemia Virus) antigen, FIV(Feline Immunodeficiency Virus)antibody, Mad Cow disease marker, CSF(Classical Swine Fever) antibodyand antigen, B. canis(Brucellocis canis) antibody and antigen, Johnesdisease antibody and BVDV(Bovine Viral Diarhrea Virus). Antigen. Alsothis invention covers detection of the cancer markers, hormones, enzymeand drugs, and antigens that may be applied as disease or biologicalmakers.

Chromatographic Material Transports Liquids

The invention disclosed herein provides assay devices and methodswherein strips of chromatographic material capable of transportingliquids are used in the assay. In one embodiment of the presentinvention, the assay device includes test sample application pads thatare in fluid flow contact with the strip which functions to regulate theflow of the test sample to the chromatographic material, to filter thetest samples and to deliver and/or mix assay reagents. For example, notmeant to limit the invention in any way, during a binding assay thelabeled reagent is contained in the application pad and is released fromthe pad to the strip containing the applied test sample, therebyeliminating the need to combine the test sample and labeled reagentprior to using the device (FIG. 3).

In a further embodiment of the invention the assay reagents areincorporated within the chromatographic material, as well as in theapplication pad. By varying the configuration of reagent-containingsites on the device, qualitative and quantitative displays of assayresults are obtained. The reagents are situated in the devices in such away as to make the assay substantially self-performing and to facilitatethe detection and quantitation of the assay results. Any signalresulting from the reaction(s) at the reagent-containing site(s) isdetected by instrumentation or by direct visual observation.

Test Device For Diagnosis Of FMD

In one embodiment the test device for the assay includes, but is notlimited to, a nitrocellulose membrane strip upon which are placed, andallowed to dry in separate distinct capture areas, highly purifiedrecombinant antigens derived from FMDV and/or specific monoclonalantibodies to FMDV (FIG. 2). The test device further includes a filterpad which contains a labeled indicator, such as gold colloid conjugatedwith protein G and/or A, suspended in a fluid containing nitrocelluloseblocking proteins, which have been dried prior to assembly and affixedto the distal end of the nitrocellulose membrane (FIGS. 2 and 3). Theentire device is held permanently in place by a top clear laminatingmaterial which bears an adhesive surface in contact with the top surfaceof the nitrocellulose membrane and attached to the conjugate pad, and abottom laminating material which bears an adhesive surface in contactwith the bottom surface of the nitrocellulose membrane. The fluid testsample flows from the distal end to the proximal end. In one embodimentof the device, there is a test sample pad and reactivity zone upon whichthe test sample is placed. The read out (in the capture areas and/or inthe test sample reactivity zone) is either visual, without the aid oflaboratory equipment, or automated. In a further embodiment of theinvention, the test device is enclosed in a casing of molded plastic orother suitable material.

Analyte Detection

An exemplary embodiment of the present invention, which is not meant todefine or constrain the invention described herein, is performed asfollows. A test sample, such as, but not limited to, animal serum iscontacted with the labeled indicator, such as protein G and/or proteinA-gold conjugate, on the filter pad at the sample application point onthe test device. IgG and/or IgM antibodies in the sample are bound bythe protein G and/or protein A-gold conjugate and the protein G and/orprotein A-gold conjugate--antibody complexes are chromatographed alongthe length of the absorbent pad (such as, but not limited to, anitrocellulose membrane). As an internal control for efficacy, a labeledcontrol reagent is also present in the filter pad. As the fluid,containing both the aforementioned complexes and the internal controlreagent, flow, they pass over the line where the FMDV recombinantantigens have been applied in test band 13 (FIG. 3). If the complexescontain specific antibody (IgG and/or IgM) to the recombinant antigensin the test band 13, the antigens in the test band will form a complexwith the protein G and/or A antibody complex and a detectable signal isgenerated. Simultaneously, the labeled control reagent present in thefluid will flow, via capillary action, to the control band 14 wherein animmobilized control capture reagent will bind to the labeled controlreagent, generating a positive signal. A further embodiment of theinvention disclosed herein incorporates the quantitation of the antibodyand/or antigen in the test sample, as determined by the intensity of thesignal generated relative to an intensity of signals generated in astandard curve.

EXAMPLES

Oligonucleotides for gene construction and sequencing were synthesizedat ResGen (Huntsville, Ala.). Unless otherwise indicated, DNA sequencingwas also performed at ResGen.

Polymerase Chain Reaction (PCR)

For PCR, Vent DNA polymerase and buffer were purchased from New EnglandBiolabs, Inc. (Beverly, Mass.) and a mixture of dNTPs was purchased fromAmersham-Pharmacia (Piscataway, N.J.) and used according to themanufacturer's specifications, unless otherwise indicated. PCRamplifications were performed on a GeneAmp 2400 thermal cycler fromPerkin-Elmer Corporation (Foster City, Calif.). The PCR product waspurified using Qiagen PCR spin column (Qiagen Inc., Chatsworth, Calif.),as recommended by the manufacturer. Unless indicated otherwise,restriction enzymes were purchased from New England BioLabs and DNAfragments were initially isolated on agarose (Sigma-Aldrich) gels priorto the restriction digestion for their cloning.

ISOLATION OF THE DESIRED CLONE(S)

The desired fragment was excised and the DNA was extracted with a QIAEXII gel extraction kit, as recommended by the manufacturer. DNA wasresuspended in H₂O or TE.

Ligation of the isolated fragment into the vector was performed usingDNA ligase (Boehringer Mannheim Corporation, Indianapolis, Ind.), asrecommended by the manufacturer. The ligation reaction was incubated at16° C. overnight. Bacterial transformations were performed using E. coliXL1-Blue competent cells. Unless indicated otherwise, transformationsand bacterial re-streaks were plated on LB agar (Lennox) platessupplemented with 100 ug/ml ampicillin. All bacterial incubations(plates and liquid cultures) were conducted overnight (16 hours) at 37°C.

Screening of transformants to identify desired clones was accomplishedby restriction enzyme digestion of mini-prep DNA and/or by colony PCR.Mini-prep DNA was prepared according to Molecular Cloning: A LaboratoryManual, unless otherwise indicated. Colonies containing desired cloneswere propagated from the transfer plate or stocked in glycerol at −70°C.

Example 1 Antigen Production Preparation Of Recombinant FMDV VP1 Antigen

A. Construction Of FMDV VP1 Expression Vectors

(i) Construction Of Synthetic VP1 Gene

VP1 protein FMDV Taiwan Type O 97 sequence was retrieved from NCBIGenBank database (genbank accession number: GI5921457) andoligonucleotides for synthesis of the gene were synthesized at ResGen(Huntsville, Ala.). In the synthetic oligonucleotides, the native FMDVcodons were altered to conform to E. coli codon bias in an effort toincrease expression levels of the recombinant protein in E. coli. (see,for example, M. Gouy and C. Gautier, Nucleic Acids Research 10:7055(1982); H. Grosjean and W. Fiers, Gene 18:199 (1982); J. Watson et al.(eds.), Molecular Biology of the Gene, 4th Ed., Benjamin KummingPublishing Co., pp. 440 (1987)). The recursive PCR method was used toassemble the oligonucleotides into a full VP1 gene. The geneconstruction strategy involved synthesis of a series of overlappingoligonucleotides with complementary ends. When annealed, the ends servedas primers for the extension of the complementary strand. The fragmentswere then amplified by outside primers.

The oligonucleotide was designed to contain a BamHI restriction site forcloning into the expression vector pGEX-4T-1. The anti-senseoligonucleotide contains a translational termination codon (TAA) and anEcoRI restriction site. When outside primers TW97-1 (SEQ ID NO: 1) andTW97-16 (SEQ ID NO: 16) were used, a full-length VP1 (213 amino acids)gene was synthesized (FIG. 4).

Recursive PCR (100 ul volume) was set up as follows: Vent DNA polymerase(1U) and 1X buffer, along with 25 uM of each dNTP (dATP, dCTP, dGTP, anddTTP), 50 pmol each of oligonucleotides TW97-1 (SEQ ID NO: 1) andTW97-16 (SEQ ID NO: 16), and 0.25 pmol each of oligonucleotides TW97-2through TW97-15 (SEQ ID NO: 2 through SEQ ID NO: 15, respectfully). Thereaction was incubated at 95° C. for 5 minutes, and then amplified with30 cycles of 95° C. for 15 seconds, 58° C. for 15 seconds and 72° C. for60 seconds, followed by incubation at 72° C. for 5 minutes. ThePCR-derived product was purified using Qiagen PCR spin column.

(ii) Cloning Of The PCR Product.

The PCR product amplified as described herein was digested with therestriction endonucleases Bam HI and Eco RI and ligated into thegel-purified vector pGEX-4T-1 that had been digested with Bam HI and EcoRI. The ligation product was used to transform XL-1 Blue competentcells. The transformed cells were plated on LB plates supplemented with100 ug/ml ampicillin. Mini-prep DNAs were prepared from overnightcultures of colonies and digested with Bam HI and Eco RI to screen thedesired clones. The clone with right insert was designated aspBM-VP1Tw97F (FIG. 5).

The pBM-VP1Tw97F clone was sequenced with the oligonucleotide primerspGEX5 (SEQ ID NO: 116) and pGEX3 (SEQ ID NO: 117).

B. Growth And Induction of E. coli Strains With VP1 Plasmids

Overnight seed cultures of each E. coli colonies were prepared in 500 mlsterile LB supplemented with 100 μg/ml ampicillin, and placed in ashaking orbital incubator at 37° C. Fifty milliliter inoculums from seedcultures were transferred to flasks containing 0.5 liter sterile LBsupplemented with 100 μg/ml ampicillin. Cultures were incubated at 37°C. until the cultures reached mid-logarithmic growth and then inducedwith 1 mM IPTG for 3 hours at 37° C. After the induction period, cellswere pelleted by centrifugation and harvested following standardprocedures currently used in the art. Pelleted cells were stored at −70°C. until further processed.

C. Preparation Of VP1 Antigen

Frozen cells obtained above were resuspended in PBS with 1 mM PMSF. Thecells were disrupted by ultrasonication (Branson). Inclusion bodies wereseparated from soluble proteins by centrifugation. These pelletedinclusion bodies were washed and pelleted sequentially in PBS followedby water. The washed inclusion bodies were resuspended in PBS and 5 Murea with a brief sonication. The inclusion bodies were then separatedfrom the solubilized proteins by centrifugation. The pelleted inclusionbodies were fully solubilized in 7M guanidine-HCl. The solubilizedrecombinant antigens were clarified by centrifugation and passed througha 0.2 μm filter.

The guanidine-HCl solubilized fusion protein was denatured by dilutingin water and precipitated by centrifugation. The pellet was washed withwater and then resuspended in water. A 2M NaOH solution was added tosolubilize the denatured protein completely and 2N HCl was added toneutralize the pH of the protein solution.

Example 2 Preparation Of Recombinant FMDV 2C Antigen

A. Construction of FMDV 2C Expression Vector

The genome sequence of FMDV 2C protein was retrieved from NCBI GenBankdatabase (GI: 5921457, O strain Chu-Pei) and oligonucleotides for thesynthesis of the entire 2C gene were synthesized, and confirmed bysequencing, at ResGen (Huntsville, Ala.). The coding DNA sequence is 954nucleotides long, which encodes 318 amino acids (FIG. 6).

(i) Construction Of Synthetic Full-Length 2C Gene

To obtain the 2C gene of FMDV, 24 oligonucleotide primers weresynthesized, each with complementary ends, at Resgen. The recursive PCRmethod was used to assemble the oligonucleotides into a full-length 2Cgene. The gene construction strategy involved synthesis of a series ofoverlapping oligonucleotides with complementary ends. When annealed, theends served as primers for the extension of the complementary strand.The fragments were then amplified by excessive outside primers.

Due to the large size of the 2C gene that was to be synthesized, theoligonucleotides were divided into three groups and the respectiverecursive PCRs were performed. The three DNA products were designated asthe A, B and C fragments. The B and C fragments were joined with PCR andthen the B-C fragment was joined with A fragment to produce afull-length 2C gene. One of the oligonucleotides on the end of thefull-length gene was designed to contain a BamHI restriction site forcloning into the expression vector pGEX-4T-1. The reaction was incubatedat 95° C. for 5 minutes, and then amplified with 35 cycles of 95° C. for30 seconds, 53° C. for 30 seconds and 73° C. for 100 seconds, followedby incubation at 73° C. for 5 minutes. An aliquot of the reactionmixture was analyzed by electrophoresis on agarose mini-gel.

(ii) Cloning of the PCR Product.

The amplified PCR product as described herein was digested with therestriction endonucleases Bam HI and Hind III and ligated into thevector pGEX-4T-1 that had been digested with Bam HI and Hind III. Theligation product was used to transform E. coli XL-1 Blue competentcells. The transformed cells were plated on LB plates supplemented with100 ug/ml ampicillin. Mini-prep DNAs were prepared from overnightcultures of transformed colonies using QIAprep plasmid DNAmini-preparation kit and digested with Bam HI and Hind III to screen thedesired clones. The clone with right insert was designated aspBM-2CTw97F (FIG. 7).

The pBM-2CTw97F clone was sequenced with the oligonucleotide primerspGEX5 (SEQ ID NO: 116), pGEX3 (SEQ ID NO: 117), 2C-25 (SEQ ID NO: 41)and 2C-26 (SEQ ID NO: 42).

B. Growth and Induction of E. coli Strains with FMDV 2C Plasmid

Overnight seed cultures of pGEX-2CTw97F were prepared in 500 ml sterileLB supplemented with 100 ug/ml ampicillin, and placed in a shakingorbital incubator at 37° C. A 50 ml inoculum from seed cultures wastransferred to flask containing 0.5 liter sterile LB supplemented with100 μg/ml ampicillin. Cultures were incubated at 37° C. until it reachedmid-logarithmic growth and then induced with 1 mM IPTG for 3 hours at37° C. After the induction period, cells were pelleted by centrifugationand harvested following standard procedures. The pelleted cells werestored at −70° C. until further process.

C. Preparation of FMDV 2C Antigen

Frozen cells obtained above were resuspended in PBS with 1 mM PMSF andTriton X-100 detergent, and then disrupted by ultrasonication (Branson).Inclusion bodies were separated from soluble proteins by centrifugation.The protein fraction enriched with 2C was obtained through 3-4 rounds ofwashing off the contaminants and solubilization of the cell lysatepellet in urea or guanidin-HCl. Recombinant 2C was purified through sizeexclusion chromatography (FPLC, Sephacryl S 200 HR) under denaturingconditions (5N GuHCl, PBS (pH7.4)) and the eluted fraction containing 2Cwas identified by SDS-PAGE and then dialyzed against 20 mM phosphatebuffer (pH 9.0). Sodium azide (0.05%) was added to the protein solution,which was stored at 4° C. For longer storage (over 1 month), the proteinsolution was aliquoted and frozen at −70° C.

Example 3 Preparation of Recombinant FMDV 3ABC Antigen

A. Construction of FMDV 3ABC expression vector

The genome sequence of FMDV 3ABC protein was retrieved from NCBI GenBankdata (GI: 5921457, O strain Chu-Pei) and oligonucleotides for thesynthesis of whole 3ABC gene and sequencing were synthesized at ResGen(Huntsville, Ala.). The coding DNA sequence is 1281 nucleotides long,which encodes 427 amino acids (FIG. 8).

(i) Construction of synthetic full-lenth 3ABC genes

To obtain the 3ABC gene of FMDV, 33 oligonucleotide primers weresynthesized, each with complementary ends, at ResGen. The recursive PCRmethod was used to assemble the oligonucleotides into a full-length 3ABCgene. The gene construction strategy involved synthesis of a series ofoverlapping oligonucleotides with complementary ends. When annealed, theends served as primers for the extension of the complementary strand.The fragments then were amplified using outside primers. Due to thelarge size of 3ABC gene to be synthesized, the oligonucleotides weredivided into four groups and respective recursive PCRs were performed.The four DNAs were designated as the A, B, C or D fragment. The A and Bfragments were joined and the C and D fragments were joined through PCR.Then the A-B fragment was joined with the C-D fragment to produce afull-length 3ABC gene.

One of the end oligonucleotides used in the recursive PCR above wasdesigned to contain a BamHI restriction site for cloning into theexpression vector pGEX-4T-1. The anti-sense oligonucleotide contains atranslational termination codon (TAA) and an EcoRI restriction site.When N-and C- terminal primers, 3ABC-1 (SEQ ID NO: 43) and 3ABC-33 (SEQID NO: 75), were used, a full-length 3ABC (427 amino acids) gene wassynthesized.

The PCR reaction (100 μl volume) was set up as follows: Vent DNApolymerase (1U) and 1X buffer, along with 25 μM of each dNTP (dATP,dCTP, dGTP, and dTTP), 4 μl 100 mM MgSO₄ and 100 pmol of eacholigonucleotide. The template was mixture of the A-B fragment and theC-D fragment. The reaction was incubated at 95° C. for 5 minutes, andthen amplified with 35 cycles of 95° C. for 30 seconds, 60° C. for 30seconds and 73° C. for 120 seconds, followed by incubation at 73° C. for5 minutes. The PCR-derived product was run on the agarose gel and theDNA band was excised and eluted from the gel using Quigen gel extractionkit.

(ii) Cloning of the PCR Product.

The PCR product amplified as described above was digested with therestriction endonucleases Bam HI and Hind III and ligated into thevector pGEX-4T-1 that had been digested with Bam HI and Hind III. Theligation product was used to transform E. coli XL-1 Blue competentcells. The transformed cells were plated on LB plates supplemented with100 μg/ml ampicillin. Mini-prep DNAs were prepared from overnightcultures of transformed colonies using QIAprep plasmid DNAmini-preparation kit and digested with Bam HI and Hind III to screen forthe desired clones. The clone with right insert was designated aspBM-3ABCTw97F (FIG. 9).

The pBM-3ABCTw97F clone was sequenced with the oligonucleotide primerspGEX5 (SEQ ID NO: 116), pGEX3 (SEQ ID NO: 117), 3ABC-36 (SEQ ID NO: 78)and 3ABC-37 (SEQ ID NO: 79).

B. Growth and Induction of E. coli Strains with 3ABC Plasmid

Overnight seed cultures of pGEX-3ABCTw97F were prepared in 500 mlsterile LB supplemented with 100 μg/ml ampicillin, and placed in ashaking orbital incubator at 37° C. A 50 ml inoculum from seed cultureswas transferred to flask containing 0.5 liter sterile LB supplementedwith 100 μg/ml ampicillin. Cultures were incubated at 37° C. until itreached mid-logarithmic growth and then induced with 1 mM IPTG for 3hours at 37° C. After the induction period, cells were pelleted bycentrifugation and harvested following standard procedures known in theart. Pelleted cells were stored at −70° C. until further process.

C. Preparation of FMDV 3ABC Antigen

Frozen cells obtained above were resuspended in PBS with 1 mM PMSF andTriton X-100 detergent and disrupted by ultrasonication (Branson).Inclusion bodies were separated from soluble proteins by centrifugation.Protein fraction enriched with 3ABC was obtained through 3-4 rounds ofwashing off the contaminants and solubilization of cell lysate pellet inurea. Recombinant 3ABC was run through ion-exchange chromatography(FPLC, Q-Sepharose FF) under denaturing condition (8 M urea, 10 mM DTT,20 mM potassium phosphate, pH 7.0) and eluted using a NaCl gradient. Theeluted fraction was dialyzed against 20 mM phosphate buffer (pH 9.0).After measuring the protein concentration by the Bradford method andadding sodium azide to 0.05%, the protein solution was stored at 4° C.For longer storage (over 1 month), protein solution was aliquoted andfrozen at −70° C.

Example 4 Preparation of Recombinant FMDV 3D Antigen

A. Construction of FMDV 3D Expression Vector

(i) Construction of Synthetic full-length 3D Genes

To obtain the 3D gene of FMDV, 36 oligonucleotides were syntheszied,each with complementary ends, at ResGen. We used the recursive PCRmethod to assemble the oligonucleotides into a full 3D gene (FIG. 10).The gene construction strategy involved synthesis of a series ofoverlapping oligonucleotides with complementary ends. When annealed, theends served as primers for the extension of the complementary strand.The fragments were then amplified by excessive outside primers. Becauseof the large size of 3D gene to be synthesized, the oligonucleotideswere divided into three groups and recursive PCRs were performed. Theproduced DNAs were designated as the A, B and C fragments. The B and Cfragments were joined with PCR and then the B-C fragment was joined withthe A fragment to produce the full-length 3D gene.

One of the end oligonucleotides was designed to contain a BamHIrestriction site for cloning into the expression vector pGEX-4T-1. Theanti-sense oligonucleotide contains a translational termination codon(TAA) and an EcoRI restriction site. When N-and C- terminal primers,3d-1A (SEQ ID NO: 80) and 3d-36A (SEQ ID NO: 115), were used, afull-length 3D (470 amino acids) gene was synthesized. These steps aredetailed herein below.

1.3DA Fragment PCR

The PCR reaction (100 μl volume) was set up as follows: Vent DNApolymerase (1U) and 1×buffer, along with 25 μM of each dNTP (dATP, dCTP,dGTP, and dTTP), 4 μl 100 mM MgSO₄, 100 pmol each of oligonucleotides3d-1A (SEQ ID NO: 80) and 3d-14 (SEQ ID NO: 93). The template was amixture of 0.83 pmole of each of the oligonucleotides 3d-1A to 3d-14.The reaction was incubated at 95° C. for 5 minutes, and then amplifiedwith 35 cycles of 95° C. for 30 seconds, 53° C. for 30 seconds and 73°C. for 100 seconds, followed by incubation at 73° C. for 5 minutes. Analiquot of the reaction mixture was analyzed by electrophoresis onagarose mini-gel.

2.3DB Fragment PCR

The PCR reaction (100 μl volume) was set up as follows: Vent DNApolymerase (1U) and 1X buffer, along with 25 μM of each dNTP (dATP,dCTP, dGTP, and dTTP), 4 μl 100mM MgSO₄, 100 pmol each ofoligonucleotides 3d-13 (SEQ ID NO: 92) and 3d-24 (SEQ ID NO: 103). Thetemplate was mixture of 0.83 pmole of each oligonucleotides 3d-13 to3d-24. The reaction was incubated at 95° C. for 5 minutes, and thenamplified with 35 cycles of 95° C. for 30 seconds, 55° C. for 30 secondsand 72° C. for 90 seconds, followed by incubation at 72° C. for 5minutes. An aliquot of the reaction mixture was analyzed byelectrophoresis on agarose mini-gel.

3.3DC Fragment PCR

The PCR reaction (100 μl volume) was set up as follows: Vent DNApolymerase (1U) and 1X buffer, along with 25 μM of each dNTP (dATP,dCTP, dGTP, and dTTP), 4 μl 100 mM MgSO₄, 100 pmol each ofoligonucleotides 3d-25 (SEQ ID NO: 104) and 3d-36A (SEQ ID NO: 115). Thetemplate was mixture of 0.83 pmole of each oligonucleotides 3d-25 to3d-36A. The reaction was incubated at 95° C. for 5 minutes, and thenamplified with 35 cycles of 95° C. for 30 seconds, 53° C. for 30 secondsand 73° C. for 100 seconds, followed by incubation at 73° C. for 5minutes. An aliquot of the reaction mixture was analyzed byelectrophoresis on agarose mini-gel.

4.3DB-C Fragment PCR

The PCR reaction (100 ul volume) was set up as follows: Vent DNApolymerase (1U) and 1X buffer, along with 25 μM of each dNTP (dATP,dCTP, dGTP, and dTTP), 4 μl 100 mM MgSO₄, 100 pmol each ofoligonucleotides 3d-13 (SEQ ID NO: 92) and 3d-36A (SEQ ID NO: 115). Thetemplate was a mixture of the B and C fragments described above. Thereaction was incubated at 95° C. for 5 minutes, and then amplified with35 cycles of 95° C. for 30 seconds, 55° C. for 30 seconds and 73° C. for90 seconds, followed by incubation at 73° C. for 5 minutes. An aliquotof the reaction mixture was analyzed by electrophoresis on agarosemini-gel.

5. Full-Length 3D (ABC) PCR

The PCR reaction (100 μl volume) was set up as follows: Vent DNApolymerase (1U) and 1X buffer, along with 25 μM of each dNTP (dATP,dCTP, dGTP, and dTTP), 4 μl 100 mM MgSO₄, 100 pmol each ofoligonucleotides 3d-1A (SEQ ID NO: 80) and 3d-36A (SEQ ID NO: 115). Thetemplate was a mixture of A, B and C fragments. The reaction wasincubated at 95° C. for 5 minutes, and then amplified with 35 cycles of95° C. for 30 seconds, 60° C. for 30 seconds and 73° C. for 120 seconds,followed by incubation at 73° C. for 5 minutes. The PCR-derived productwas run on the agarose gel and the DNA band was cut from the gel andthen eluted using Quigen gel extraction kit.

(ii) Cloning of the PCR Product.

The PCR product amplified as described herein was digested with therestriction endonucleases Bam HI and Eco RI and ligated into the gelpurified vector pGEX-4T-1 that had been digested with Bam HI and Eco RI.The ligation product was used to transform XL-1 Blue competent cells.The transformed cells were plated on LB plates supplemented with 100μg/ml ampicillin. Mini-prep DNAs were prepared from overnight culturesof colonies and digested with Bam HI and Eco RI to screen the desiredclones. The clone with right insert was designated as pBM-3DTw97F (FIG.11).

B. Growth And Induction of E. coli Strains with pBM-3DTw97F

To express recombinant GST-3D protein, the pBM-3DTw97F plasmid wastransformed into E. coli BL21(DE3) and transformants were plated onLB-agar plate supplemented with 100 μg/ml ampicillin. Overnight seedcultures of the pBM-3DTw97F clone were prepared in 500 ml sterile LBsupplemented with 100 μg/ml ampicillin, and placed in a shaking orbitalincubator at 37° C. Fifty milliliter inoculums from seed cultures weretransferred to flasks containing 0.5 liter sterile LB supplemented with100 μg/ml ampicillin. Cultures were incubated at 37° C. until thecultures reached mid-logarithmic growth and then induced with 1 mM IPTGfor 3 hours at 37° C. After the induction period, cells were pelleted bycentrifugation and harvested following standard procedures. Pelletedcells were stored at −70° C. until further processed.

C. Preparation of GST-3D Protein

Frozen cells obtained above were resuspended in PBS with 1 mM PMSF. Thecells were lysed by sonication (Branson, model S-125). A soluble crudelysate was prepared by centrifugation of the cell-lysate (10,000 rpm, 30min) and filtered with 0.45 μm syringe filter (Sartorius). Glutathioneaffinity chromatography was carried out to purify rGST-3D protein. Thesoluble cell lysate was loaded onto glutathione sepharose 4B (Pharmacia)column equilibrated with PBS. After washing the column with three bedvolumes of PBS, GST-3D was eluted with 10 mM reduced glutathione, 50 mMTris-HC1, pH 8.0 buffer solution. The eluted fractions were analyzed onthe 8% SDS-PAGE. The fractions that contained the fusion protein weredialyzed in PBS overnight.

Example 5 FMDV Antibody Detection Kit Formulation

A. Preparation of Antigen Printed Membrane

From the stock solution, recombinant 2C and 3ABC were mixed to 0.5 mg/mleach with 20 mM phosphate buffer (pH 9.0) and filtered through 0.22 μmfilter unit Millex-GV (Millipore). An avidin solution (0.5 mg/ml) in PBS(pH 7.4) was used as an internal control. The antigen mixture andcontrol solution were applied to the nitrocellulose membrane (S&S, 8 μmin pore size or equivalent) using Bio-Dot equipment (Bio-Dot) andfollowing the manufacturers protocol. After the sample was dried in alow humidity room overnight, the membrane was blocked with 3% BSA in PBSfor 20 min and then dried on a fan at least for 2 hours. The processedmembrane plates are stored in an enclosed container with desiccant orlow humidity room.

B. Preparation of Protein G and/or Protein A-Gold Conjugate

Recombinant protein G and/or protein A that had been engineered toeliminate any non-specific binding to serum albumin was purchased fromSigma and reconstituted with 10 mM sodium carbonate buffer (pH 9.6) to aconcentration of 1 mg/ml. A gold particle suspension was adjusted to pH9.0 with 50 mM potassium carbonate (pH 9.6) and the protein G and/orprotein A was then added dropwise to the gold solution while stirring.The protein G and/or protein A was added so that a final concentrationof 10 μg/ml was obtained. The solution was further stirred for 15 min.Next, 30 μl of 15% BSA solution was added per ml of gold particlesuspension. After stirring for another 15 min, coupled gold solution wascentrifuged and the supernatant was discarded, thereby removing anyunbound protein G and/or protein A. To the pellet of 200 ml of coupledgold solution, 12 ml of 2% BSA (in deionized water) was added. Thepellet solution was then sonicated in a sonic bath (Branson model #2200or equivalent) to resuspend the pellet. The suspension was centrifugedagain and the final pellet was suspended in the same volume of 2% BSA(10mM Sodium carbonate, pH 9.6) and stored in refrigerator.

C. Preparation of Biotin-BSA-Gold Conjugate: Control Indicator

Biotinylated BSA (Pierce) was purchased and was coupled to the gold. Theconjugation procedures were basically the same as described as forprotein G and/or protein A above. Ten micrograms of biotinylated BSA perml of gold particle suspension was added to the gold solution, which hadbeen adjusted to pH 4.4 by adding 40 mM phosphoric acid with vigorousstirring. After about 1 min, 16.6 μl of 40 mM potassium carbonate per mlof coupled gold solution was added and allowed to stir for 10-15 min. Atthe end of the coupling reaction, 30 μl of 15% BSA solution was addedper ml of gold particle suspension. After stirring for another 15 min,the Biotin-BSA coupled gold conjugate suspension was centrifuged and thesupernatant was discarded to remove any unbound Biotin-BSA. The pelletfrom 200 ml of coupled gold solution was washed with 12 ml of 2% BSA (10mM Sodium phosphate, pH 7.5). The resultant pellet was then resuspendedin the same volume of 2% BSA (10 mM Sodium phosphate, pH 7.5) and storedin refrigerator.

D. Preparation of the Dye-Pad

Protein G and/or protein A coupled gold solution was diluted using dyedilution buffer (1% casein, 100 mM sodium phosphate, pH 7.0). Biotin-BSAcoupled gold solution was added to generate the control line, whichbinds to avidin on the membrane (see FIG. 3). A lysate of the same E.coli strain used for production of recombinant FMDV antigens, butwithout a recombinant plasmid, was added to eliminate any anti-E. coliantibodies that might be present in the sample. The diluted goldsolution was spread onto the Lydall pad strip (microglass paper) anddried in a lyophilizer. The Lydall pad was pre-soaked in pretreatmentbuffer (1% NP-40, 20 mM EDTA, 0.25% L-7600, 1% PVP 10, 10 mM sodiumphosphate and 0.1% sodium azide, pH 7.0), excess liquid was blotted off,and the pad was dried on a fan. The pad is stored in a low humidity roomuntil use.

E. Filter Pad Preparation

The cellulose filter paper was pre-soaked in pretreatment buffer (0.5%NP-40, 2% B-lactose, 1% PEG 15K, 100 mM sodium phosphate, and 0.1%sodium azide, pH 7.0) excess liquid was blotted off, and the paper wasdried on a fan. The prepared filter pad was stored in a low humidityroom.

F. Device Assembly

A protective sheet at the top of the plate was peeled off and theabsorbent pad was attached along the long axis of the plate. Aprotective sheet at the bottom of the plate was peeled off and the dyepad was attached beneath the test membrane area along the long axis ofthe plate. The dye pad should overlap the bottom of the test membraneabout 2-3 mm. Next, the filter pad was attached to the plate to coverthe bottom of the dye pad. Finally, the dressed membrane plate was cutinto 0.765 cm wide strips (FIG. 2).

Example 6 Kit Assay

A schematic diagram of the test kit is shown in FIG. 12. A test samplecontaining antibodies to FMDV or infected with FMDV (membrane shown onthe left) will display a positive signal when contacted with FMDVantigen or FMDV antibodies, respectively. This is indicated by the colorreaction at the band containing the immobilized capture reagent (FMDVantigen or FMDV antibodies; T), whereas a sample that does not containFMDV (membrane shown on the right) will not display any color at thetest band (T). A positive control is incorporated into the test kit byapplying an albumin-biotin gold conjugate to the filter pad containingthe labeled reagent. The albumin-biotin gold conjugate will bind to theavidin in the control band, thus the control band will be positive inboth the test strips.

FIG. 13 is a schematic diagram of a two-line test kit configuration. Ananimal infected with FMDV, as shown in the figure labeled “infected”,will reveal a positive signal on both the T1 (which contains SPs VP1 or3D) and T2 (which contains NSPs 2C or 3ABC) test bands. The vaccinatedsample will only reveal a positive signal at the T1 test band. Noantibodies to NSPs and no NSP antigens will be present in the vaccinatedsample. Thus the present invention is able to differentiate, within avery short time period, between the infected animal and one that isimmune to infection (i.e., has been vaccinated).

Results Analysis of Whole Blood and Serum Samples in FMDV-InfectedAnimals

Both whole blood and serum samples from FMDV-infected sheep (3) andgoats (3) were analyzed for the presence of antibodies to thenon-structural proteins 2C and 3ABC (Tables 1 and 2).

TABLE 1 Results Of Pen-Side Test Using Whole Blood And Serum SamplesFrom FMDV-Infected Sheep Ovine #716 Ovine #717 Ovine #718 Whole WholeWhole DPI blood serum blood serum blood serum 0 — — — — — — 2 — — — — —— 4 — — — — — — 6 — — — — — — 8 + ± — — — — 10 + + — — + + 12 + + ±± + + 14 ++ ++ ++ ++ ++ ++ Legend: +++ Prominently Visible Line ++Clearly Visible Line + Detectable Line ± Unclear Line — No Line

TABLE 2 Results Of Pen-Side Test Using Whole Blood And Serum SamplesFrom FMDV-Infected Goats Caprine #804 Caprine #808 Caprine #809 WholeWhole Whole DPI blood serum blood serum blood serum 0 — — — — — — 2 — —— — — — 4 — — — — — — 6 — — — — — — 8 + + — — — — 10 + + + + ± + 12 + +++ ++ ++ ++ 14 ++ ++ ++ ++ ++ ++ Legend: +++ Prominently Visible Line ++Clearly Visible Line + Detectable Line ± Unclear Line — No Line

A positive signal was first detected at 8 days post infection (DPI) inovine #716. There was no difference in the results from a whole bloodsample or a serum sample.

Antibodies in ovine #717 were also detected, although a positive signalwas not detected until 12 DPI. The antibodies in the whole blood andserum samples were detected at the same time after infection.

Antibodies in ovine #718 were detected at 10 DPI. As in ovine #716 and#717, the antibodies in the whole blood and serum samples were detectedon the same DPI after infection.

The time frame in which the antibodies to the non-structural proteins inFMDV were detected in the goats (Table 2) was similar to those describedfor the sheep (Table 1). The anti-non-structural protein antibodies inthe three goats were detected in both the whole blood and serum betweenday 8 and day 10 post infection.

Performance Characteristics Of The Assay

A total of 1540 identified clinical samples from cattle, swine, goat andsheep sera, provided by PIADC, were tested at the Plum Island AnimalDisease Center, USDA (Greenport, N.Y.) using the assay of the inventionand commercially available ELISA.

The samples were negative samples prior to vaccination, vaccinatedsamples that were not infected, and infected samples. The results, shownin Table 3 below, illustrate the excellent agreement between the assayof the invention and the reference ELISA.

The assay of the invention demonstrated a relative sensitivity of 98.6%(69/70) and relative specificity of 98.6% (1449/1470) when compared withthe reference test. The overall accuracy was 98.6% (1518/1540). (seealso Table 4)

TABLE 3 Rapid Immunoassay vs. ELISA Test Results Rapid Immunoassay ELISA(AHIS Plum Island) Positive Negative Total Positive Negative TotalInfected (+) 52 0 52 52 0 52 Naïve (−) 8 1003 1011 0 1011 1011Vaccinated (−) single multi 1 109 110 0 110 110 6 64 70 0 70 70 Total 671176 1243 52 1191 1243

Sensitivity And Specificity Of The Test Device

The sensitivity and specificity of the assay device disclosed herein wasdetermined on the basis of samples that had been previously tested usingthe standard test method (ELISA). Antibodies against the 3ABC protein(one of the non-structural proteins) were measured 10 DPI using themethod disclosed herein. The results shown in Table 4 reveal that theassay method of the present invention provides a sensitive, accurate andspecific assay system that distinguishes, simultaneously, between aninfected animal and one that is protected from infection (i.e.,vaccinated) in a single step within 30 minutes.

TABLE 4 The Sensitivity And Specificity Of The Pen-Side Test For Bovine,Swine, Ovine, And Caprine Relative (%) Bovine Swine Ovine CaprineSensitivity 95.6 (22/23)  100 (12/12) 100 (13/13)  100 (8/8) Specificity98.5 (316/320)) 99.3 (796/801) 100 (31/31) 96.8 (30/31) Accuracy 98.8(338/343) 99.3 (808/813) 100 (43/43) 97.4 (38/39)

Efficacy Of The Assay Device

FIGS. 14-17 compare the efficacy of the standard ELISA test to that ofthe assay presented herein. Antibodies to 3ABC were detected 6-7 DPI inbovine #19 and 21 (FIGS. 14-15), whereas the standard ELISA remainednegative until 9 DPI. FIGS. 16-17 show the efficacy of the assay inpigs. Antibodies were detected in swine #183 12 DPI, whileseroconversion in swine #186 was detected 10 DPI. While efficacy of theELISA method was similar, the results of this method are not availablefor a few days. The results of the assay of the invention are availablewithin 30 minutes, a significant advantage since FMDV is highlycontagious and will spread rapidly through a herd.

The foregoing descriptions of specific embodiments of the presentinvention have been presented for the purposes of illustration anddescription. They are not intended to be exhaustive or to limit theinvention to the precise forms disclosed, and obviously manymodifications and variations are possible in light of the aboveteaching. The embodiments were chosen and described in order to bestexplain the principles of the invention and its practical application,to thereby enable others skilled in the art to best utilize theinvention and various embodiments with various modifications as aresuited to the particular use contemplated. It is intended that the scopeof the invention be defined by the claims appended hereto and theirequivalents.

1. A method for qualitatively measuring an amount of an analyte ofinterest for presence of FMDV in a sample, comprising: a. obtaining afluid test sample to be assayed for said analyte of interest; b.supplying a rapid measurement device comprising a membrane strip with aproximal end containing a labeled binding partner and a labeled controlreagent, and a distal end containing a band of an immobilized capturereagent comprising at least one of VP1, 3D, 2C or 3ABC, and a secondband of immobilized control capture reagent, wherein said fluid testsample moves from said proximal end to said distal end by capillaryaction; c. contacting said membrane strip with said fluid test sample;d. maintaining said membrane strip under conditions which are sufficientto allow said analyte of interest to bind to said labeled bindingpartner, forming a specific binding complex, and to allow fluid totransport said specific binding complex and said labeled control reagentin said fluid by capillary action through said membrane strip to saidimmobilized capture reagent and said immobilized control capturereagent; e. maintaining said membrane strip under conditions which aresufficient to allow said specific binding complex in said fluid to bindto said immobilized capture reagent and said labeled control reagent tobind to said immobilized control capture reagent; and f. detecting anamount of said analyte of interest in said fluid test sample and anamount of internal control signal, as indicated by an intensity of asignal producing system.
 2. The method of claim 1 wherein said labeledbinding partner is at least one of VP1, VP2, VP3, VP4, Lb, 2B, 2C, 3A,3D, 3AB, or 3ABC.
 3. The method of claim 1 wherein said labeled bindingpartner is protein G and/or protein A.
 4. The method of claim 1 whereinsaid analyte of interest comprises an anti-FMDV antibody.
 5. The methodof claim 4 wherein said anti-FMDV antibody is specific for anon-structural FMDV protein.
 6. The method of claim 5 wherein saidanti-FMDV antibody is specific for said nonstructural FMDV proteincomprising at least one of Lb, 2B, 2C, 3A, 3AB, 3ABC, or 3D.
 7. Themethod of claim 1 wherein said membrane strip comprises an applicationpoint comprising a filter pad containing at least one of said labeledbinding partner and said labeled control reagent.
 8. A method forsimultaneously detecting and differentiating between analytes comprisingantibodies to FMDV structural proteins and antibodies to FMDVnon-structural proteins in a sample, comprising: a. obtaining a fluidtest sample to be assayed for said antibodies of interest; b. supplyinga rapid measurement device comprising a membrane strip with a proximalend containing a labeled binding partner and a labeled control reagent,and a distal end containing a zone having at least one immobilizedcapture reagent specific for an FMDV structural protein comprising atleast one of VP1, VP2, VP3 or VP4, and a second zone having at least oneimmobilized capture reagent specific for an FMDV non-structural proteincomprising at least one of Lb, 2B, 2C, 3A, 3AB, or 3ABC, and a thirdband of immobilized control capture reagent wherein said fluid testsample moves from said proximal end to said distal end by capillaryaction; c. contacting said membrane strip with said fluid test sample;d. maintaining said membrane strip under conditions which are sufficientto allow said analyte of interest to bind to said labeled bindingpartner, forming a specific binding complex, and to allow fluid totransport said specific binding complex and said labeled control reagentin said fluid by capillary action through said membrane strip to saidimmobilized capture reagent specific for an FMDV structural protein andsaid adjacent immobilized capture reagent specific for an FMDVnon-structural protein and to said immobilized control capture reagent;e. maintaining said membrane strip under conditions which are sufficientto allow said specific binding complex in said fluid to bind to at leastone of said immobilized capture reagent specific for an FMDV structuralprotein and/or to bind to at least one of said immobilized capturereagent specific for an FMDV non-structural protein and said labeledcontrol reagent to bind to said immobilized control capture reagent; f.detecting an amount of said analyte of interest in said fluid testsample and an amount of internal control signal, as indicated by anintensity of a signal producing system; and g. differentiating betweensaid antibodies to FMDV structural proteins and said antibodies to FMDVnon-structural proteins.
 9. The method of claim 8 wherein said labeledbinding partner is at least one of VP1, 3D, 2C or 3ABC and at least oneof VP1, VP2, VP3 and VP4.
 10. The method of claim 8 wherein said labeledbinding partner is protein G and/or protein A.
 11. The method of claim 8wherein said membrane strip comprises an application point comprising afilter pad containing at least one of said labeled binding partner andsaid labeled control reagent.
 12. A method for quantitatively measuringan amount of an analyte of interest in a sample for differentiating FMDVinfection from FMDV vaccination, comprising: a. obtaining a fluid testsample to be assayed for said analyte of interest; b. supplying a rapidmeasurement device comprising a membrane strip with a proximal endcontaining a labeled binding partner and a labeled control reagent, anda distal end containing a band of an immobilized capture reagentcomprising at least one of VP1, 3D, 2C or 3ABC, and a second band ofimmobilized control capture reagent, wherein said fluid test samplemoves from said proximal end to said distal end by capillary action; c.contacting said membrane strip with said fluid test sample; d.maintaining said membrane strip under conditions which are sufficient toallow said analyte of interest to bind to said labeled binding partner,forming a specific binding complex, and to allow fluid to transport saidspecific binding complex and said labeled control reagent in said fluidby capillary action through said membrane strip to said immobilizedcapture reagent and said immobilized control capture reagent; e.maintaining said membrane strip under conditions which are sufficient toallow said specific binding complex in said fluid to bind to saidimmobilized capture reagent and said labeled control reagent to bind tosaid immobilized control capture reagent; and f. quantitating an amountof said analyte of interest in said fluid test sample as indicated by anintensity of a signal producing system generated in said fluid testsample relative to an intensity of signals generated in a standardcurve.
 13. The method of claim 12 wherein said labeled binding partneris at least one of VP1, 3D, 2C or 3ABC.
 14. The method of claim 12wherein said labeled binding partner is protein G and/or protein A. 15.The method of claim 12 wherein said analyte of interest comprises ananti-FMDV antibody.
 16. The method of claim 15 wherein said anti-FMDVantibody is specific for a nonstructural FMDV protein.
 17. The method ofclaim 14 wherein said anti-FMDV antibody is specific for saidnonstructural FMDV protein comprising at least one of 2C, 3A, 3ABC or3D.
 18. The method of claim 12 wherein said membrane strip comprises anapplication point comprising a filter pad containing at least one ofsaid labeled binding partner and said labeled control reagent. 19-50.(canceled)